



We understand the importance our medicines and continuity of care have for patients and families. That is why, as promised, we are committed to sharing timely and transparent updates on our Norditropin® supply situation.

Due to manufacturing delays, we are unable to supply additional Norditropin® product to the U.S. market, beyond the limited quantity already available, in January and February 2023. Supply will restart in mid-March and continue through April, May and June. We expect to meet demand by the end of June and foresee a stable supply of Norditropin® throughout the second half of this year.

We know this is a challenging situation for you, your loved ones, and this patient community, and take our responsibility to resolve it very seriously. We remain committed to doing everything we can to get back to a stable supply of Norditropin® as quickly as possible to meet your needs. This includes ramping up production capacity at a new state-of-the-art manufacturing facility.

If you have concerns about what to do next, please reach out to your healthcare professional to discuss the best path forward.

We care about this community, understand this is difficult, and again, are committed to resolving this situation so patients can access this important medicine. We will proactively share updates if there are any changes in Norditropin® supply status.